Bio-Path (BPTH) Q3 2025 earnings summary

Executive summary

• Focused on RNAi nanoparticle drug development for oncology and obesity, with four drug candidates in the pipeline targeting multiple cancer indications and obesity-related metabolic diseases.

• Lead candidate prexigebersen is in Phase 2 trials for AML, with promising interim results; other candidates include BP1002, BP1003, and BP1001-A.

• Instituted an operational pause and furloughed most employees in June 2025 due to capital constraints, with ongoing efforts to secure additional funding.

• Recent management changes include the appointment of Vikram Grover as CEO and CFO in October 2025.

Financial highlights

• Net loss for Q3 2025 was $1.0 million, down from $2.1 million in Q3 2024; net loss for the nine months ended September 30, 2025 was $8.4 million, compared to $7.1 million in the prior year period.

• Research and development expenses for Q3 2025 were $0.3 million, a $1.0 million decrease year-over-year, mainly due to paused clinical trials.

• General and administrative expenses for Q3 2025 were $0.2 million, a $1.1 million decrease year-over-year, reflecting reduced corporate activity.

• Cash balance as of September 30, 2025 was $0.0 million, down $1.2 million from December 31, 2024.

Outlook and guidance

• Expects to continue incurring significant operating losses and will require substantial additional capital to fund ongoing and future operations.

• Uncertainty remains regarding the ability to raise additional funds; failure to do so may result in further operational reductions or curtailment of programs.